RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA (1) and Releases 2026 Financial Guidance Total Company Revenue increased 14.8% to a quarterly record of $547.

RadNet Reports Fourth Quarter 2025 Results,

Including Record Revenue and Adjusted EBITDA(1) and Releases 2026 Financial Guidance

LOS ANGELES, California, March 2, 2026 -

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging

services through a network of 418 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter

and full-year ended December 31, 2025.

Dr. Howard Berger, President and Chief Executive Officer

of RadNet, commented, "I am very pleased with the fourth quarter performance. Relative to last year's fourth quarter, Total

Company Revenue increased 14.8% and Adjusted EBITDA(1) increased 16.9%, resulting in margin improvement of 29 basis points.

This performance was driven by strong aggregate and same center procedural growth, combined with a continued focus on driving operating

and clinical efficiencies within the Imaging Center segment. These factors, amongst others, contributed to RadNet exceeding 2025 Revenue

and Adjusted EBTIDA(1) guidance levels in the Imaging Center segment, which had been amended upwards throughout the year."

Dr. Berger continued, "During the fourth quarter,

we continued to experience increasing demand for our services in virtually all core markets, and operations teams were focused on improving

patient-throughput and driving capacity at existing centers. In particular, disproportionately higher demand for advanced imaging continues

to benefit our procedure mix, evidenced by a 178 basis point increase in MR, CT and PET/CT as a percentage of our overall procedure volume

when compared with the fourth quarter of last year. At the same time, during the fourth quarter and throughout 2025, significant investments

were made to open new centers and complete tuck-in acquisitions within virtually all core RadNet markets. RadNet centers continue to implement

DeepHealth technology solutions to drive efficiencies, lower costs and automate manual processes. This includes the comprehensive roll-out

of TechliveTM, See-Mode and other clinical and workflow tools designed to increase productivity, create capacity and decrease

exposure to the challenging labor market. In the coming quarters, as we continue to implement many of these solutions internally, we will

have the opportunity to demonstrate the power of improved automation and more advanced clinical and operational capabilities, which we

believe will lead to more favorable patient care and health outcomes, improved service levels to referring physicians, further alignment

with health system partners and closer relationships with insurance plans and other payors."

"Moving into 2026, RadNet is well-positioned

to accelerate growth within Digital Health. With the addition of products resulting from this morning's acquisition of Gleamer in

Paris, France, the Digital Health division now includes what we believe to be the most comprehensive and broad collection of clinical

AI solutions of any company worldwide. This will have broad implications for the performance of RadNet's core Imaging Center business,

the businesses of the over 2,700 current Digital Health customers and future customers throughout the diagnostic imaging industry. The

diagnostic imaging industry will transform in the coming years as a result of an industry-wide adoption of the kind of AI-powered workflow

and clinical tools that RadNet is acquiring, developing, utilizing and commercializing. We intend to continue to develop and bring-to-market

solutions that address the critical challenges the industry faces, including labor shortages, capacity constraints and the inability of

radiologists to keep pace with growing industry volumes, all in an effort to improve patient care and outcomes," concluded Dr. Berger.

Fourth Quarter Report:

For the fourth quarter of 2025, RadNet reported Total

Company Revenue of $547.7 million and Adjusted EBITDA(1) of $87.7 million. Revenue increased $70.6 million (or 14.8%) and Adjusted

EBITDA(1) increased $12.7 million (or 16.9%) as compared with the fourth quarter of 2024.

For the fourth quarter of 2025, RadNet reported Digital

Health Revenue of $27.9 million (inclusive of intersegment revenue) and Adjusted EBITDA(1) of $4.9 million. Revenue increased

$9.1 million (or 48.2%) and Adjusted EBITDA(1) increased $0.4 million (or 8.9%) as compared with the fourth quarter of 2024.

There were a number of unusual or one-time items impacting

the fourth quarter including: $531,000 in severance expense related to cost-savings initiatives; $233,000 impairment loss on lease abandonment;

$788,000 expense related to leases for de novo facilities under construction that have yet to open their operations; $2.3 million of acquisition

transaction costs; $6.5 million loss on sale and disposal of equipment; $6.3 million of non-capitalized research and development expenses

related to the DeepHealth products; $679,000 of non-cash loss from interest rate swaps; and $5.7 million adjustment to the tax provision

to normalize nonrecurring and prior year tax adjustments. Adjusting for the above items, Total Company Adjusted Earnings(3)

was $18.1 million and diluted Adjusted Earnings Per Share(3) was $0.23 during the fourth quarter of 2025. This compares with

Total Company Adjusted Earnings(3) of $18.1 million and diluted Adjusted Earnings Per Share(3) of $0.24 during the

fourth quarter of 2024.

Unadjusted for unusual or one-time items impacting

the fourth quarter, Total Company Net Loss for the fourth quarter of 2025 was $0.6 million as compared with a Total Company Net Income

of $5.3 million for the fourth quarter of 2024. Fully diluted Net Loss Per Share for the fourth quarter of 2025 was $(0.01), compared

with a fully diluted Net Income per share of $0.07 in the fourth quarter of 2024, based upon a weighted average number of diluted shares

outstanding of 76.6 million shares in 2025 and 75.5 million shares in 2024.

For the fourth quarter of 2025, as compared with the

prior year's fourth quarter, MRI volume increased 15.8%, CT volume increased 10.3% and PET/CT volume increased 28.3%. Overall volume,

taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 7.0% over the prior

year's fourth quarter. On a same-center basis, including only those centers which were part of RadNet for both the fourth quarters

of 2025 and 2024, MRI volume increased 11.4%, CT volume increased 6.3% and PET/CT volume increased 14.3%. Overall same-center volume,

taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 4.5% over the prior

year's same quarter.

For full-year 2025, RadNet reported Total Company

Revenue of $2,040.2 million and Adjusted EBITDA(1) of $300.2 million. Revenue increased $210.5 million (or 11.5%) and Adjusted

EBITDA(1) increased $20.8 million (or 7.4%) as compared with full-year 2024.

For full-year 2025, RadNet reported Digital Health

Revenue (inclusive of intersegment revenue) of $92.7 million and Adjusted EBITDA(1) of $15.5 million. Revenue increased $27.0

million (or 41.1%) and Adjusted EBITDA(1) increased $0.3 million (or 1.9%) as compared with full-year 2024. At December 31,

2025, Annual Recurring Revenue(4) (ARR) for the Digital Health was $75.4 million, representing 81.3% of 2025 Revenue.

Unadjusted for one-time or unusual items, Total Company

Net Loss for 2025 was $18.7 million as compared with a Total Company Net Income of $2.8 million in 2024. Fully diluted Net Loss Per Share

for 2025 was $(0.25), compared with a Net Income per share of $0.04 in 2024, based upon a weighted average number of diluted shares outstanding

of 75.2 million shares in 2025 and 74.8 million shares in 2024.

Actual 2025 Results vs. 2025 Guidance

Imaging Center Segment

Digital Health Segment

RadNet reports 2026 guidance ranges as follows:

Imaging Center Segment

Dr Berger added, "Within the Imaging Center

segment, we expect 2026 performance to benefit from the contribution of continued increases in same-center performance, further tuck-in

acquisitions, reimbursement efforts driving more favorable pricing and de novo center openings. As a result, our guidance implies 2026

Revenue to grow 17%-19%, Adjusted EBITDA(1) to grow 18%-22% and Free Cash Flow(2) to grow 29%-41% as compared with

2025 full year performance. We are anticipating this strong growth despite headwinds embedded in the guidance levels from projected increases

in same-center labor costs as well as the recent impact of severe winter weather conditions experienced in January and February."

Digital Health Segment

"Within the Digital Health segment, 2026 growth

will be driven by sales of the DeepHealth portfolio of AI-powered workflow and clinical solutions and related products such as TechLiveTM

and further contribution from the acquisitions of iCAD, See-Mode, CIMAR and Gleamer. We are anticipating a minimum of four FDA clearances

during 2026, further advancing our leadership in radiology clinical AI solutions in the areas of mammography, lung, prostate, thyroid,

brain and, with this morning's announced acquisition of Gleamer, the musculoskeletal system. In 2026, significant infrastructure

investments will continue to be made in building sales, marketing and implementation teams to support future growth. Despite the continued

focus it takes to invest in building the infrastructure of the business, 2026 Digital Health guidance implies growth of Revenue between

45% and 55% from 2025 full-year performance. We anticipate ARR at December 31, 2026 to approach or exceed $140 million. Furthermore, we

expect that the proportion of Digital Health's Revenue coming from RadNet's Imaging Center segment will decline from approximately

45% in 2025 to about 33% in 2026," concluded Dr. Berger.

Conference Call Today

Dr. Howard Berger, President and Chief Executive Officer,